Seladelpar
| Clinical data | |
|---|---|
| Pronunciation | /ˌsɛləˈdɛlpɑːr/ SEL-ə-DEL-par |
| Trade names | Livdelzi, others |
| Other names | MBX-8025; RWJ-800025 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a624062 |
| License data |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H23F3O5S |
| Molar mass | 444.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Seladelpar, sold under the brand name Livdelzi, is a medication used for the treatment of primary biliary cholangitis. It is used as the lysine dihydrate salt. It is a peroxisome proliferator-activated receptor delta (PPARδ) receptor agonist. The compound was licensed from Janssen Pharmaceutica NV.
Seladelpar was approved for medical use in the United States in August 2024.